With
a market size of US$14.5 billion in 2005 and an
anticipated value of US$16.5 billion in 2006, the
neurodegenerative market represents a valuable,
fast-growing opportunity in the pharma/biotech industry.
An increase in the number of aged people, increased
life expectancy, unmet clinical needs together with
advances in treatments of neurodegenerative diseases,
such as Alzheimer’s and Parkinson’s disease will
continue to contribute to the expansion of the global
market.
This
report provides an insight into the neurodegenerative
market, neurotherapeutic drugs currently available,
and upcoming products. This report specifically
focuses on key CNS diseases, such as Alzheimer’s
disease, Parkinson’s disease, multiple sclerosis,
amyotrophic lateral sclerosis, Huntington’s disease,
and neuropathies.
Profiles
of leading companies that are active in R&D in these
areas are included. The report presents, in detail,
an overview of the current global market for neurodegenerative
drugs for selected neurological diseases, including
currently marketed and forthcoming neurotherapeutic
products. Market analysis and assessment for key
neurodegenerative therapies is done across major
pharmaceutical markets in United States (US)/North
America, Europe and Japan.
Key
features of this report:
-
Statistical
information for selected neurological diseases
-
Overview of the disease, key therapies, market
size and growth, market composition by region,
as well as market outlook and forecast
-
Global
sales figures for key neurodegenerative therapies
-
Financial
forecasts by disease and key product
-
Description
of neurotherapeutic products currently on the
market, including a description of products in
the pipeline
-
Company
profiles of major pharmaceutical providers active
in R&D in these areas
-
The
report also deals with factors affecting growth,
new drug therapies, and clinical research in the
completion stages.
The
diseases/conditions addressed in the report include:
|
